

**REPORT OF THE DIRECTORS AND**  
**AUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2022**  
**FOR**  
**ONYX SCIENTIFIC LIMITED**

**ONYX SCIENTIFIC LIMITED**

**CONTENTS OF THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2022**

	<b>Page</b>
<b>Company Information</b>	1
<b>Report of the Directors</b>	2
<b>Report of the Independent Auditors</b>	3
<b>Income Statement</b>	5
<b>Other Comprehensive Income</b>	6
<b>Balance Sheet</b>	7
<b>Statement of Changes in Equity</b>	8
<b>Cash Flow Statement</b>	9
<b>Notes to the Cash Flow Statement</b>	10
<b>Notes to the Financial Statements</b>	11
<b>Trading and Profit and Loss Account</b>	17

**ONYX SCIENTIFIC LIMITED**  
**COMPANY INFORMATION**  
**FOR THE YEAR ENDED 31 MARCH 2022**

**DIRECTORS:** Mrs D Bowser  
Dr D J Londesbrough  
N V Lane  
P Godha

**REGISTERED OFFICE:** Units 97-98 Silverbriar  
Sunderland Enterprise Park East  
Sunderland  
Tyne and Wear  
SR5 2TQ

**REGISTERED NUMBER:** 03947634 (England and Wales)

**AUDITORS:** Leesing Marrison Lee Limited  
Chartered Certified Accountants  
Statutory Auditors  
46 Main Street  
Mexborough  
South Yorkshire  
S64 9DU

**BANKERS:** HSBC  
33 Park Row  
Leeds  
West Yorkshire  
LS1 1LD

**ONYX SCIENTIFIC LIMITED**  
**REPORT OF THE DIRECTORS**  
**FOR THE YEAR ENDED 31 MARCH 2022**

The directors present their report with the financial statements of the company for the year ended 31 March 2022.

**DIVIDENDS**

The total distribution of dividends for the year ended 31 March 2022 will be £2,000,000.

**DIRECTORS**

The directors shown below have held office during the whole of the period from 1 April 2021 to the date of this report.

Mrs D Bowser  
Dr D J Londesbrough  
N V Lane  
P Godha

**STATEMENT OF DIRECTORS' RESPONSIBILITIES**

The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS**

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

**AUDITORS**

The auditors, Leasing Morrison Lee Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

**ON BEHALF OF THE BOARD:**

  
.....  
P Godha - Director

Date: 20<sup>th</sup> May 2022  
.....

**ONYX SCIENTIFIC LIMITED**  
**STRATEGIC REPORT**  
**FOR THE YEAR ENDED 31 MARCH 2022**

The directors present their strategic report for the year ended 31 March 2022.

The company (Onyx Scientific) is engaged in contract research, custom synthesis and contract manufacturing services for Active Pharma Ingredients (API) and Intermediates for the pharmaceutical industry.

**BUSINESS REVIEW AND FINANCIAL KEY PERFORMANCE INDICATORS**

Financial key performance indicators are set out below:

	2022 £000	2021 £000
Financial Performance		
Revenue	12,760	9,972
Operating profit	3,172	2,721
Profit for the financial year	2,606	2,290
	No.	No.
Employee numbers at 31 March	87	68

The company increased revenues by 28% during the financial year. To support this growth in activity, headcount increased by 19 over the year.

Despite the global uncertainty, we invested significantly in expanding our service offering.

Onyx continues to experience strong interest in the business offering. In FY22 several new customers were added to the portfolio.

**Other key performance indicators**

Health, safety and environmental compliance and performance remain key priorities for the business. All related performance indicators remained under good control.

During FY22 the number of customer audits was significantly fewer than the norm, due to the global pandemic. However those that took place (virtually) were successfully completed without any critical or major observations. In every instance supply approval was granted confirming Onyx's commitment to quality.

**Future outlook**

Based upon the current order position, the directors are confident that the company will continue to increase sales and profitability.

Strict controls remain in place to protect employees and the business during the COVID-19 pandemic. We continue to monitor national and global developments to ensure we can respond and adapt quickly again if needed.

**PRINCIPAL RISKS AND UNCERTAINTIES**

The company is exposed to a range of risks and uncertainties. The directors must assess these risks and ensure appropriate controls and processes are in place to monitor the risks and mitigate their effect. The principal risks and mitigating controls are as follows:

**COVID-19**

COVID-19 remains a threat within the UK. Onyx continues to employ strict working practices and procedures aimed at protecting employees and the business. To date these measures have proved to be effective and business activities have continued as normal.

**Cyber security**

A loss of a key business system could impact our ability to manufacture products and lead to customer disappointment and reputational damage. Onyx mitigates this risk through investment in robust security controls and procedures, security testing arrangements and ongoing employee training.

**Trading risk I customer dependency**

The timing of drug approval by government agencies may affect the phasing of sales. The company continues to mitigate this risk by the expansion and diversification of its customer base and product portfolios.

**ONYX SCIENTIFIC LIMITED**  
**STRATEGIC REPORT**  
**FOR THE YEAR ENDED 31 MARCH 2022**

**FINANCIAL RISKS**

Credit risk

The company is exposed to credit risk from its trade debtors and from depositing cash with banking institutions. Customers are assessed for credit-worthiness before credit is extended, and any debts which become overdue are chased promptly. Likewise, the company only engages with banks that can demonstrate a strong financial position and developments in the sector are monitored closely.

**DIRECTORS' STATEMENT OF COMPLIANCE TO PROMOTE THE SUCCESS OF THE COMPANY**

The directors of Onyx - and those of all UK companies - must act in accordance with a set of general duties. These duties are detailed in the UK Companies Act and include a duty to promote the success of the company for the benefit of its members as a whole. Details of how the directors have fulfilled this responsibility are set out below:

**BOARD COMPOSITION**

The directors of Onyx work closely with the group board of its parent company Ipca UK Ltd, the quarterly review board meetings regularly include representatives from Ipca UK and Ipca Ltd. A broad representation brings a range of experiences and view-points to decision making, and ensures that a balanced approach is taken, which considers the interests of all shareholders and stakeholders.

**ON BEHALF OF THE BOARD:**

  
.....  
Dr D J Londesbrough - Director

Date: 20<sup>th</sup> May 2022  
.....

## **REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF ONYX SCIENTIFIC LIMITED**

### **Opinion**

We have audited the financial statements of Onyx Scientific Limited (the 'company') for the year ended 31 March 2022 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 March 2022 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

### **Other information**

The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

### **Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF  
ONYX SCIENTIFIC LIMITED**

**Responsibilities of directors**

As explained more fully in the Statement of Directors' Responsibilities set out on page four, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

**Auditors' responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our procedures to respond to risks identified include the following;

reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;

enquiring of management concerning actual and potential litigation and claims;

performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

reading minutes of meetings of those charged with governance and reviewing regulatory correspondence;


obtained an understanding of provisions and held discussions with management to understand the basis of recognition or non-recognition of tax provisions; and

in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Auditors.

**Use of our report**

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Robert Tippett FCCA (Senior Statutory Auditor)  
for and on behalf of Leesing Marrison Lee Limited  
Chartered Certified Accountants  
Statutory Auditors  
46 Main Street  
Mexborough  
South Yorkshire  
S64 9DU

23 May 2022

**ONYX SCIENTIFIC LIMITED**

**INCOME STATEMENT  
FOR THE YEAR ENDED 31 MARCH 2022**

	Notes	2022 £	2021 £
<b>TURNOVER</b>	3	12,760,415	9,972,333
Cost of sales		6,008,739	4,377,981
<b>GROSS PROFIT</b>		6,751,676	5,594,352
Administrative expenses		3,603,892	2,884,939
		3,147,784	2,709,413
Other operating income	4	24,712	12,218
<b>OPERATING PROFIT</b>	6	3,172,496	2,721,631
Interest receivable and similar income		1,476	217
		3,173,972	2,721,848
Interest payable and similar expenses	7	-	8
<b>PROFIT BEFORE TAXATION</b>		3,173,972	2,721,840
Tax on profit	8	567,802	431,546
<b>PROFIT FOR THE FINANCIAL YEAR</b>		2,606,170	2,290,294

The notes form part of these financial statements

**ONYX SCIENTIFIC LIMITED**  
**OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 31 MARCH 2022**

	Notes	2022 £
<b>PROFIT FOR THE YEAR</b>		2,606,170
<b>OTHER COMPREHENSIVE INCOME</b>		-
<b>TOTAL COMPREHENSIVE INCOME FOR THE YEAR</b>		<u>2,606,170</u>

2021 £
2,290,294
-
<u>2,290,294</u>

The notes form part of these financial statements


**ONYX SCIENTIFIC LIMITED (REGISTERED NUMBER: 03947634)**

**BALANCE SHEET**  
**31 MARCH 2022**

	Notes	2022		2021	
		£	£	£	£
<b>FIXED ASSETS</b>					
Tangible assets	10		4,012,569		2,374,257
Investments	11		720,935		720,935
			<u>4,733,504</u>		<u>3,095,192</u>
<b>CURRENT ASSETS</b>					
Stocks	12	946,322		605,090	
Debtors	13	2,433,312		2,189,862	
Cash at bank and in hand		1,946,915		3,325,760	
			<u>5,326,549</u>	<u>6,120,712</u>	
<b>CREDITORS</b>					
Amounts falling due within one year	14	1,612,376		1,462,805	
<b>NET CURRENT ASSETS</b>			<u>3,714,173</u>		<u>4,657,907</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<u>8,447,677</u>		<u>7,753,099</u>
<b>PROVISIONS FOR LIABILITIES</b>	16		<u>411,127</u>		<u>322,719</u>
<b>NET ASSETS</b>			<u>8,036,550</u>		<u>7,430,380</u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital	17		368,122		368,122
Share premium	18		12,358		12,358
Retained earnings	18		7,656,070		7,049,900
			<u>8,036,550</u>		<u>7,430,380</u>
<b>SHAREHOLDERS' FUNDS</b>			<u>8,036,550</u>		<u>7,430,380</u>

Approved and authorised for issue by the Board of Directors and authorised for issue on .....  
and were signed on its behalf by:

*20th May 2022*

  
.....  
N V Lane - Director

  
.....  
Mrs D Bowser - Director

  
.....  
Dr D J Londesbrough - Director

  
.....  
P Godha - Director

The notes form part of these financial statements

**ONYX SCIENTIFIC LIMITED**

**STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 31 MARCH 2022**

	Called up share capital £	Retained earnings £	Share premium £	Total equity £
<b>Balance at 1 April 2020</b>	368,122	4,759,606	12,358	5,140,086
<b>Changes in equity</b>				
Total comprehensive income	-	2,290,294	-	2,290,294
<b>Balance at 31 March 2021</b>	<u>368,122</u>	<u>7,049,900</u>	<u>12,358</u>	<u>7,430,380</u>
<b>Changes in equity</b>				
Dividends	-	(2,000,000)	-	(2,000,000)
Total comprehensive income	-	2,606,170	-	2,606,170
<b>Balance at 31 March 2022</b>	<u>368,122</u>	<u>7,656,070</u>	<u>12,358</u>	<u>8,036,550</u>

The notes form part of these financial statements

**ONYX SCIENTIFIC LIMITED**

**CASH FLOW STATEMENT  
FOR THE YEAR ENDED 31 MARCH 2022**

	Notes	2022 £	2021 £
<b>Cash flows from operating activities</b>			
Cash generated from operations	1	2,772,906	4,040,751
Interest paid		-	(8)
Tax paid		(332,546)	(393,341)
Net cash from operating activities		<u>2,440,360</u>	<u>3,647,402</u>
<b>Cash flows from investing activities</b>			
Purchase of tangible fixed assets		(2,365,837)	(815,120)
Monies to Ipca Laboratories (UK) Ltd		545,156	(545,156)
Interest received		1,476	217
Net cash from investing activities		<u>(1,819,205)</u>	<u>(1,360,059)</u>
<b>Cash flows from financing activities</b>			
Equity dividends paid		(2,000,000)	
Net cash from financing activities		<u>(2,000,000)</u>	
<b>(Decrease)/increase in cash and cash equivalents</b>		<u>(1,378,845)</u>	<u>2,287,343</u>
<b>Cash and cash equivalents at beginning of year</b>	2	<u>3,325,760</u>	<u>1,038,417</u>
<b>Cash and cash equivalents at end of year</b>	2	<u><u>1,946,915</u></u>	<u><u>3,325,760</u></u>

The notes form part of these financial statements

**ONYX SCIENTIFIC LIMITED**

**NOTES TO THE CASH FLOW STATEMENT  
FOR THE YEAR ENDED 31 MARCH 2022**

**1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS**

	2022	2021
	£	£
Profit before taxation	3,173,972	2,721,840
Depreciation charges	727,525	459,537
Finance costs	-	8
Finance income	(1,476)	(217)
	<u>3,900,021</u>	<u>3,181,168</u>
(Increase)/decrease in stocks	(341,232)	100,875
(Increase)/decrease in trade and other debtors	(788,606)	96,057
Increase in trade and other creditors	2,723	662,651
	<u>2,772,906</u>	<u>4,040,751</u>
<b>Cash generated from operations</b>	<u>2,772,906</u>	<u>4,040,751</u>

**2. CASH AND CASH EQUIVALENTS**

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

**Year ended 31 March 2022**

	31.3.22	1.4.21
	£	£
Cash and cash equivalents	<u>1,946,915</u>	<u>3,325,760</u>

**Year ended 31 March 2021**

	31.3.21	1.4.20
	£	£
Cash and cash equivalents	<u>3,325,760</u>	<u>1,038,417</u>

**3. ANALYSIS OF CHANGES IN NET FUNDS**

	At 1.4.21	Cash flow	At 31.3.22
	£	£	£
<b>Net cash</b>			
Cash at bank and in hand	3,325,760	(1,378,845)	1,946,915
	<u>3,325,760</u>	<u>(1,378,845)</u>	<u>1,946,915</u>
<b>Total</b>	<u>3,325,760</u>	<u>(1,378,845)</u>	<u>1,946,915</u>

The notes form part of these financial statements

## **ONYX SCIENTIFIC LIMITED**

### **NOTES TO THE FINANCIAL STATEMENTS** **FOR THE YEAR ENDED 31 MARCH 2022**

#### **1. STATUTORY INFORMATION**

Onyx Scientific Limited is a private company, limited by shares and registered in England and Wales. The company's registered number is 03947634 and the registered office address can be found on the company information page.

#### **2. ACCOUNTING POLICIES**

##### **Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

##### **Turnover**

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

##### **Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Improvements to property	- 10% on cost
Plant and machinery	- at varying rates on cost and at variable rates on reducing balance
Fixtures and fittings	- 25% on reducing balance
Motor vehicles	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

##### **Investments in associates**

Investments in associates is recognised at impaired cost.

##### **Research and development**

Expenditure on research and development is written off in the year in which it is incurred.

##### **Foreign currencies**

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

##### **Hire purchase and leasing commitments**

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

##### **Pension costs and other post-retirement benefits**

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

##### **Grants**

Grants relating to revenue items are credited to the Profit and Loss Account in the same accounting period as the expenditure to which the grant relates. Grants in respect of Capital items are credited to the Profit and Loss Account over the same period as the asset to which the grant relates is written off.

##### **Stocks**

Stocks and work in progress are valued at cost, determined on a first in first out basis, after making the appropriate allowance for obsolete and slow moving items.

Cost of work in progress consists of direct costs and an appropriate proportion of fixed and variable overheads.

##### **Deferred tax**

Deferred tax is recognised in respect of all material timing differences that have originated but have not reversed at the balance sheet date.

**ONYX SCIENTIFIC LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2022**

**3. TURNOVER**

The turnover and profit before taxation are attributable to the one principal activity of the company.

An analysis of turnover by geographical market is given below:

	2022	2021
	£	£
United Kingdom	7,180,415	5,560,686
America & Rest of World	1,620,000	1,152,208
Europe	3,960,000	3,259,439
	<u>12,760,415</u>	<u>9,972,333</u>

**4. OTHER OPERATING INCOME**

	2022	2021
	£	£
Grants	10,000	12,218
Bank charges refunded	4,950	
Insurance claims	9,762	
	<u>24,712</u>	<u>12,218</u>

**5. EMPLOYEES AND DIRECTORS**

	2022	2021
	£	£
Wages and salaries	3,015,886	2,395,627
Social security costs	319,322	249,221
Other pension costs	209,105	220,680
	<u>3,544,313</u>	<u>2,865,528</u>

The average number of employees during the year was as follows:

	2022	2021
Sales	2	2
Administration	10	9
Laboratory staff	75	57
	<u>87</u>	<u>68</u>

	2022	2021
	£	£
Directors' remuneration	396,864	331,923
Directors' pension contributions to money purchase schemes	100,031	131,372
	<u>496,895</u>	<u>463,295</u>

Information regarding the highest paid director is as follows:

	2022	2021
	£	£
Emoluments etc	141,977	127,648
Pension contributions to money purchase schemes	34,958	36,984
	<u>176,935</u>	<u>164,632</u>

**ONYX SCIENTIFIC LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2022**

**6. OPERATING PROFIT**

The operating profit is stated after charging:

	2022	2021
	£	£
Other operating leases	323,118	329,634
Depreciation - owned assets	727,525	459,538
Auditors' remuneration	7,000	6,520
Foreign exchange differences	15,564	5,636
	<u>          </u>	<u>          </u>

In addition to being remunerated for audit work the auditors charged for payroll services in the amount of £4,488 (2021: £3,242).

**7. INTEREST PAYABLE AND SIMILAR EXPENSES**

	2022	2021
	£	£
Interest on taxation	-	8
	<u>          </u>	<u>          </u>

**8. TAXATION**

**Analysis of the tax charge**

The tax charge on the profit for the year was as follows:

	2022	2021
	£	£
Current tax:		
UK corporation tax	438,450	391,601
Under provision prior year	40,944	
	<u>          </u>	<u>          </u>
Total current tax	479,394	391,601
Deferred tax	88,408	39,945
	<u>          </u>	<u>          </u>
Tax on profit	567,802	431,546
	<u>          </u>	<u>          </u>

**9. DIVIDENDS**

	2022	2021
	£	£
Ordinary shares of £1	2,000,000	
	<u>          </u>	<u>          </u>

**ONYX SCIENTIFIC LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2022**

**10. TANGIBLE FIXED ASSETS**

	Improvements to property £	Plant and machinery £	Fixtures and fittings £
<b>COST</b>			
At 1 April 2021	1,387,330	5,387,399	50,856
Additions	726,056	1,553,410	16,227
At 31 March 2022	<u>2,113,386</u>	<u>6,940,809</u>	<u>67,083</u>
<b>DEPRECIATION</b>			
At 1 April 2021	959,866	3,515,038	44,934
Charge for year	115,194	583,831	3,903
At 31 March 2022	<u>1,075,060</u>	<u>4,098,869</u>	<u>48,837</u>
<b>NET BOOK VALUE</b>			
At 31 March 2022	<u>1,038,326</u>	<u>2,841,940</u>	<u>18,246</u>
At 31 March 2021	<u>427,464</u>	<u>1,872,361</u>	<u>5,922</u>
	Motor vehicles £	Computer equipment £	Totals £
<b>COST</b>			
At 1 April 2021	-	168,380	6,993,965
Additions	16,540	53,604	2,365,837
At 31 March 2022	<u>16,540</u>	<u>221,984</u>	<u>9,359,802</u>
<b>DEPRECIATION</b>			
At 1 April 2021	-	99,870	4,619,708
Charge for year	1,868	22,729	727,525
At 31 March 2022	<u>1,868</u>	<u>122,599</u>	<u>5,347,233</u>
<b>NET BOOK VALUE</b>			
At 31 March 2022	<u>14,672</u>	<u>99,385</u>	<u>4,012,569</u>
At 31 March 2021		<u>68,510</u>	<u>2,374,257</u>

**11. FIXED ASSET INVESTMENTS**

	Interest in associate £
<b>COST</b>	
At 1 April 2021 and 31 March 2022	<u>720,935</u>
<b>NET BOOK VALUE</b>	
At 31 March 2022	<u>720,935</u>
At 31 March 2021	<u>720,935</u>

**ONYX SCIENTIFIC LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2022**

**11. FIXED ASSET INVESTMENTS - continued**

During the 2018 accounting year the Company acquired 10% common stock of Pisgah Laboratories Inc. (Pisgah) based out of North Carolina, USA. Pisgah was originally founded in the year 1981 as a contract manufacturer and developer of active pharmaceutical ingredients (APIs) and intermediates and has been a chemistry solutions provider for over three decades. This acquisition will help the Company to establish its foothold in the US market (including but not limited to) in the field of research / small volume APIs and intermediates manufacturing. Pisgah will continue to operate out of its North Carolina manufacturing facility under the Pisgah trade name.

**12. STOCKS**

Stocks are stated at the lower of cost, using the first in first out method, and selling price less costs to complete and sell.

Stock consists of finished goods for resale.

**13. DEBTORS**

	2022	2021
	£	£
Amounts falling due within one year:		
Trade debtors	2,233,683	1,471,292
Other debtors	28,748	28,539
Prepayments	170,881	144,875
	<u>2,433,312</u>	<u>1,644,706</u>
Amounts falling due after more than one year:		
Amounts owed by group undertakings	-	545,156
Aggregate amounts	<u>2,433,312</u>	<u>2,189,862</u>

**14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2022	2021
	£	£
Trade creditors	756,194	767,103
Corporation Tax	188,449	41,601
Social security and other taxes	73,262	63,588
VAT	19,871	28,157
Other creditors	24,108	
Accrued expenses	550,492	562,356
	<u>1,612,376</u>	<u>1,462,805</u>

**15. LEASING AGREEMENTS**

Minimum lease payments under non-cancellable operating leases fall due as follows:

	2022	2021
	£	£
Between one and five years	<u>293,250</u>	<u>293,250</u>

**16. PROVISIONS FOR LIABILITIES**

	2022	2021
	£	£
Deferred tax	<u>411,127</u>	<u>322,719</u>

**ONYX SCIENTIFIC LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2022**

**16. PROVISIONS FOR LIABILITIES - continued**

	Deferred tax £
Balance at 1 April 2021	322,719
Charge to Income Statement during year	88,408
	<hr/>
Balance at 31 March 2022	411,127
	<hr/> <hr/>

**17. CALLED UP SHARE CAPITAL**

Allotted, issued and fully paid:				
Number:	Class:	Nominal value:	2022 £	2021 £
368,122	Ordinary	£1	368,122	368,122
			<hr/>	<hr/>

**18. RESERVES**

	Retained earnings £	Share premium £	Totals £
At 1 April 2021	7,049,900	12,358	7,062,258
Profit for the year	2,606,170		2,606,170
Dividends	<u>(2,000,000)</u>		<u>(2,000,000)</u>
At 31 March 2022	<hr/> <u>7,656,070</u>	<hr/> <u>12,358</u>	<hr/> <u>7,668,428</u>

**19. CAPITAL COMMITMENTS**

	2022 £	2021 £
Contracted but not provided for in the financial statements	1,609,434	1,609,434
	<hr/>	<hr/>

**20. RELATED PARTY DISCLOSURES**

The entire share capital of the company is owned by Ipca Laboratories (UK) Limited.

Ipca Laboratories (UK) Limited

During the year to 31 March 2022 dividends of £2,000,000 were paid to Ipca Laboratories (UK) Limited (2021: £NIL)

During the year the company repaid £545,156 to Ipca Laboratories (UK) Limited and the balance owed to group undertakings is £NIL (2021: £545,156).

**21. ULTIMATE CONTROLLING PARTY**

The company is a wholly owned subsidiary of Ipca Laboratories (UK) Limited, which is a wholly owned subsidiary of Ipca Laboratories Limited, a company listed on the Bombay stock exchange and National stock exchange of India.

**ONYX SCIENTIFIC LIMITED**

**TRADING AND PROFIT AND LOSS ACCOUNT  
FOR THE YEAR ENDED 31 MARCH 2022**

	2022		2021	
	£	£	£	£
<b>Sales</b>		12,760,415		9,972,333
<b>Cost of sales</b>				
Opening stock	26,726		29,695	
Opening work in progress	578,364		676,270	
Purchases	2,453,354		1,495,850	
Analytical and laboratory consumables	159,674		121,465	
Transport and packing	190,080		127,207	
General chemicals	391,491		280,219	
Safety consumables	86,301		82,744	
N M R consumables	3,470		2,649	
G M P consumables	36,599		30,611	
Solid State consumables	15,646		10,181	
Wages	2,312,373		1,786,839	
Social security	231,669		177,362	
Pensions	91,687		77,128	
Analytical services	254,927		84,851	
Commission	122,700			
	6,955,061		4,983,071	
Closing stock	(119,153)		(26,726)	
Closing work in progress	(827,169)		(578,364)	
		6,008,739		4,377,981
<b>GROSS PROFIT</b>		6,751,676		5,594,352
<b>Other Income</b>				
Grants	10,000		12,218	
Bank charges refunded	4,950			
Insurance claims	9,762			
Interest on bank charges refunded	1,476			
Interest on taxation	-		217	
		26,188		12,435
		6,777,864		5,606,787
<b>Expenditure</b>				
Directors' salaries	396,864		331,923	
Directors' social security	56,009		42,038	
Directors' pension contributions	100,031		131,372	
Wages	306,649		276,865	
Social security	31,644		29,821	
Pensions	17,387		12,180	
Rent	323,118		329,634	
Rates and water	100,789		93,886	
Insurance	88,976		74,682	
Light and heat	285,681		178,345	
Building services	228,124		130,678	
Telephone	10,244		9,659	
Post and stationery	27,688		16,970	
Advertising	64,100		102,063	
Motor expenses	7,143		2,248	
Repairs and renewals	574,669		473,087	
Computer expenses	66,028		66,279	
Technical literature	978		2,906	
Sundry expenses	35,095		29,897	
Professional charges	9,953		13,270	
Carried forward	2,731,170	6,777,864	2,347,803	5,606,787

This page does not form part of the statutory financial statements

**ONYX SCIENTIFIC LIMITED**

**TRADING AND PROFIT AND LOSS ACCOUNT  
FOR THE YEAR ENDED 31 MARCH 2022**

	2022		2021	
	£	£	£	£
Brought forward	2,731,170	6,777,864	2,347,803	5,606,787
Accountancy	5,852		3,242	
Healthcare costs	13,064		16,091	
Recruitment expenses	62,789		31,582	
Seminars and course fees	34,577		7,517	
Auditors' remuneration	7,000		6,520	
Currency exchange differences	15,564		5,636	
Entertainment	3,014		4,318	
		2,873,030		2,422,709
		3,904,834		3,184,078
<b>Finance costs</b>				
Bank charges	3,337		2,693	
Interest on taxation	-		8	
		3,337		2,701
		3,901,497		3,181,377
<b>Depreciation</b>				
Improvements to property	31,789		39,107	
Plant and machinery	671,194		402,497	
Motor vehicles	1,868			
Computer equipment	22,674		17,933	
		727,525		459,537
<b>NET PROFIT</b>		3,173,972		2,721,840

This page does not form part of the statutory financial statements